{"name":"Theracos","slug":"theracos","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2023-01-01","label":"Brenzavvy first approved","drug":"Brenzavvy","drugSlug":"bexagliflozin","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"oncology","drugs":[{"name":"Bexagliflozin tablets","genericName":"Bexagliflozin tablets","slug":"bexagliflozin-tablets","indication":"Type 2 diabetes mellitus","status":"marketed"},{"name":"Brenzavvy","genericName":"BEXAGLIFLOZIN","slug":"bexagliflozin","indication":"Diabetes mellitus type 2","status":"marketed"},{"name":"Placebo for Bexagliflozin","genericName":"Placebo for Bexagliflozin","slug":"placebo-for-bexagliflozin","indication":"Type 2 diabetes","status":"phase_3"},{"name":"Placebo for Glimepiride","genericName":"Placebo for Glimepiride","slug":"placebo-for-glimepiride","indication":"Control arm in clinical trials for Type 2 Diabetes Mellitus (as comparator to Glimepiride)","status":"marketed"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"EGT0001442","genericName":"EGT0001442","slug":"egt0001442","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"Bexagliflozin tablets","genericName":"Bexagliflozin tablets","slug":"bexagliflozin-tablets","phase":"marketed","mechanism":"Bexagliflozin inhibits sodium-glucose cotransporter 2 (SGLT2) in the kidney to increase urinary glucose excretion and lower blood glucose levels.","indications":["Type 2 diabetes mellitus"],"catalyst":""},{"name":"Brenzavvy","genericName":"BEXAGLIFLOZIN","slug":"bexagliflozin","phase":"marketed","mechanism":"Bexagliflozin inhibits SGLT2 to reduce renal glucose reabsorption and increase urinary glucose excretion.","indications":["Diabetes mellitus type 2"],"catalyst":""},{"name":"EGT0001442","genericName":"EGT0001442","slug":"egt0001442","phase":"phase_2","mechanism":"EGT0001442's mechanism of action is currently unknown.","indications":[],"catalyst":""},{"name":"Placebo for Bexagliflozin","genericName":"Placebo for Bexagliflozin","slug":"placebo-for-bexagliflozin","phase":"phase_3","mechanism":"Placebo does not have a known mechanism of action.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"Placebo for Glimepiride","genericName":"Placebo for Glimepiride","slug":"placebo-for-glimepiride","phase":"marketed","mechanism":"A placebo contains no active pharmaceutical ingredient and produces no direct pharmacological effect.","indications":["Control arm in clinical trials for Type 2 Diabetes Mellitus (as comparator to Glimepiride)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi9wFBVV95cUxOR1dyb2pxay1jUUNITFYyaGVTQk01RGxGQVl6bVFWZDJWRHRLVU8xZXFYZEpra1FYM3k2LW9yNzREemFPQk80R2RiSTA5YnRONi1uQmZnZVZBOFczSVF4T1dfSUpqVDZjUDB1T09zZWFqLVJ5bmxBeXZwYVUxQ3IxUzEteHpVUFZWNmt6Nm5SRnJWWTZuOHdZdHhDOEoxek9HSlV5a0N2NmF6QUxxUE5DWVJUVXdMalBHZDJxcUlIMWdCZGR3QTZsYXFOdVdRYTlhTDdNYWdRTHg1VUFPeWdYcTd4RXd4N0xxQ1IzekFPdnNOZDJKcXZR?oc=5","date":"2025-06-26","type":"regulatory","source":"Business Wire","summary":"TheracosBio Collaborates with Publix Pharmacy to Provide Affordably Priced FDA-approved Diabetes Medication - Business Wire","headline":"TheracosBio Collaborates with Publix Pharmacy to Provide Affordably Priced FDA-approved Diabetes Medication","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxOOGtzUHNmN0hwalJEWHY5a0xxT0d6ajNSWU9DZTQ0Y2p0Z2piSExIN0pYTmNMUS14YWx2WmpUVVA0ekVyejlKc2diRHdSd3VFTW5MbUlTN3FKSzc4STJFenA5R1RLbDY2MUhSLVZrUjkyUXRPUXR5VXUzR2wxOVBjOWNaVmpRVVVjLTZhdEJHSjNfSmJwVFpPM0p1aFVhWU9yWmNvaXRFOWd1aUpY?oc=5","date":"2025-06-09","type":"pipeline","source":"Medscape Reference","summary":"Addressing Partial Treatment Response in MDD Patients - Medscape Reference","headline":"Addressing Partial Treatment Response in MDD Patients","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxPN1k4SmMyQy05SDI0ZmhXNVVMR3cySWVXaUNaTzdkX1d4aUdtcEdQYkJuSGc4MnAxRTE5Nk1hejhwTDhpSGpTQUtuaE5UX0hCN3JYZDQ5Si1yOWQ4RmtIQ3h0NjYzOERKbHJrcmx2VGlxQ1g0UDJ6dW5oVjlyOE5jeVFkSUFMeXJ2REJubGwtbExSU0NuU3pEVER6dHhGaTJwTThuQXdn?oc=5","date":"2024-12-02","type":"pipeline","source":"cvc.com","summary":"CVC Completes Acquisition of Therakos from Mallinckrodt - cvc.com","headline":"CVC Completes Acquisition of Therakos from Mallinckrodt","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxQY2VsMHZNRnpDcXkyZ1ZpVzVKZXVfUFB3WWxMRzJaMTBaRGV0LUFfN0pjZ3oxRnFzdWxidUh1ZGlOeXd6Zmh2c3JvRFBSWTBsTUR4cUw1d25OdkhnTEY4MEFGZjVYUElwTTFNSVRQWEVNRFBKMVgzTUtFTGkzOHB1U3M5MWxaa2dMNnBBWkx5QWFodGNueHBCVEs0Y0FGNFVZbTIxSno4akJ4R1Vxa0d4cA?oc=5","date":"2023-08-01","type":"pipeline","source":"Worcester Business Journal","summary":"Marlborough pharma names new CEO as its diabetes drug moves to commercialization - Worcester Business Journal","headline":"Marlborough pharma names new CEO as its diabetes drug moves to commercialization","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxORU5kLXphWC1YYmdrWlktWVZSSWhrdmlSSm5qYUZrUGJidU0wRXJzNFUzUDBNVVdwUmQyNnJMN2JIN3FvRTdXVVoyNmlTQkQ4ZGRzdlVsSk5DT1J6YUdnMnFlRDNEc2NIMFJCcGRIUXRvaUJ5NDU3THA3T1dTdDFkaUZTNm9naGZtT18yZTc4T2FMcmc2cTA2clhEa2FUYmd3amM0MQ?oc=5","date":"2023-08-01","type":"pipeline","source":"Fierce Pharma","summary":"As TheracosBio launches inexpensive diabetes drug, it makes a CEO switch - Fierce Pharma","headline":"As TheracosBio launches inexpensive diabetes drug, it makes a CEO switch","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxPLVhHSnR2eHJ5WjJtbzZOTmxIcHhxUmw3aTRhVW5UOHFuR3ZEQUN4VHhKYUhUeUlaUlR4MUR4QkhwUDdtcnpwejhobm1weG1mMXNSRm1QeXVYMmxOeFVNV0FXOHBZZ3g0Rld0dzQzOXdyRHlNSmM2VmxaTU84VjBnbFR0OXZHQkVaamJETE4tN3lqUUc4M2RsT25lVzU1bDhiUzNiZVNaLWx6b0VOQnJyQjZERmpUbjA?oc=5","date":"2023-07-13","type":"pipeline","source":"Fierce Pharma","summary":"TheracosBio teams with Mark Cuban's Cost Plus to launch Brenzavvy at bargain price - Fierce Pharma","headline":"TheracosBio teams with Mark Cuban's Cost Plus to launch Brenzavvy at bargain price","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxNYy1KbGVacHF2QzIxcUdacTFsX3VST01rR0JnMjRRZmJhZDdCaGlueXJYRG5xRFVZdGJoNWUtaWVrWWs0b19mWTMtOUZYbkFRcU5UVXRjZVFmVUxNUTU3N1dDMk5GbXUweFlHQVJqX1FINUFYZHB5NGxaUFRJeWhCRmQ0TjFmTl9pZEE4N1h1ajVXQnNFYW9lN1hCSXExMHhyeVpxbG8wX1FMM1BXTnFldA?oc=5","date":"2023-01-23","type":"pipeline","source":"Fierce Pharma","summary":"With TheracosBio green light, another SGLT2 inhibitor wades into diabetes arena - Fierce Pharma","headline":"With TheracosBio green light, another SGLT2 inhibitor wades into diabetes arena","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxPdjRzUVUzR3pZdi0ta08xRkVxOWlJUl9DeXFlQ3QzTUhHX1F1ZkdURnU4cEVIME85ZzZkRHJKWjUtblI0WXF6MU1pZDdidnJTckptYktKQTVpQXh6YTFtZEtsTURpZTl0Q3hvd0RZVXJNcHBwUzIxbm9FRzRScjNIWnVXUGdmOEZoVDhWbm5BMENvZWlwelBSZFZB?oc=5","date":"2018-06-24","type":"pipeline","source":"cen.acs.org","summary":"Theracos becomes increasingly reliant on contract manufacturing as its drug advances - cen.acs.org","headline":"Theracos becomes increasingly reliant on contract manufacturing as its drug advances","sentiment":"neutral"}],"patents":[],"drugCount":5,"phaseCounts":{"marketed":3,"phase_2":1,"phase_3":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}